From the Journals

Is This Methadone’s Moment?


 

An Ethical Imperative

“With only about 2000 OTP clinics clustered in urban areas, less than 25% of people who are diagnosed with opioid use disorder are actually able to access methadone,” Caty Simon, with the National Survivors Union, Greensboro, North Carolina, and coauthor of the JAMA Viewpoint, said in an interview.

While MOTAA represents a major step forward, limiting methadone prescribing to addiction specialists may not fully address the treatment gap, particularly in rural and underserved areas, Simon said.

To optimize methadone’s potential, she’d like to see further expansion of prescribing privileges to general healthcare providers.

“As someone with lived and living experience of opioid use and treatment, and somebody who works nationally and locally in organizations of people impacted by drug use, I know people in my area right now — marginalized people of color — who would have much better chances of survival if they were able to access methadone. If MOTAA passed tomorrow, we could save so many lives. There is an ethical imperative to pass it,” Simon said.

Leshner said he is “always very concerned about access, particularly for underserved populations, poor people, people living in rural areas. If you can access the medications you need, you’re in big trouble.”

Is this methadone’s moment? “I’m a little optimistic, but I haven’t seen the progress I would like to see,” Leshner said.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Veterans Found Relief From Chronic Pain Through Telehealth Mindfulness
MDedge Neurology
The Prohibitive Price Tag
MDedge Neurology
Triptans Trump Newer, More Expensive Meds for Acute Migraine
MDedge Neurology
Muscle Relaxants for Chronic Pain: Where Is the Greatest Evidence?
MDedge Neurology
Erenumab Reduces Nonopioid Medication Overuse Headache in Chronic Migraine
MDedge Neurology
Crisugabalin Alleviates Postherpetic Neuralgia Symptoms in Phase 3 Study
MDedge Neurology
Caffeine Brings Benefits and Risks
MDedge Neurology
DIY Brain Stimulation Is Growing in Popularity, but Is It Safe, Effective?
MDedge Neurology
Duloxetine Bottles Recalled by FDA Because of Potential Carcinogen
MDedge Neurology
FDA Okays Abuse-Deterrent Opioid for Severe Pain
MDedge Neurology